Antimicrobial susceptibility testing

MICRONAUT-S MDR MRGN-Screening

Phenotypic detection of clinically relevant resistance mechanisms, including confirmation of cephalosporinases and carbapenemases in Enterobacterales and non-fermenters

Phenotypic detection of clinically relevant cephalosporinases and carbapenemases

In recent years there has been an increase in multi-drug resistance (MDR) amongst gram-negative pathogens. This has impacted both hospital and community acquired infections.

The MICRONAUT-S MDR MRGN Screening plate provides an extended spectrum of critically important back-up antibiotics and meropenem screening concentrations for an improved detection of OXA-48-like type D carbapenemases.

It also offers an extended spectrum of antibiotics by introduction of the novel antibiotic combinations ceftazidime-avibactam and ceftolozane-tazobactam. 

MIC plate for AST of multi-drug resistant gram-negative bacteria (MDR phenotype)

The MICRONAUT-S MDR MRGN Screening plate offers a range of features and benefits relating to the phenotypic detection of clinically relevant resistance mechanisms. 

  • Resistance determination of all relevant gram-negative bacteria (Enterobacteria, Aeromonas, non-fermenters) against antibiotics and antibiotics combinations in a standard microdilution procedure
  • AST against the novel antibiotic combinations ceftazidime-avibactam and ceftolozane-tazobactam
  • Phenotypical detection of MBL (metallo-ß-lactamases) by resistance determination against meropenem as a mono substance and in combination with the divalent cationic chelator EDTA
  • Phenotypical detection of KPC (Klebsiella pneumoniae carbapenemase) by resistance determination against meropenem as a mono substance and in combination with 3-Amino-Phenyl-Borate (3-APB)
  • Phenotypical detection of AMP-C (Aminopenicillin inactivating cephalosporinase) by the susceptibility testing with 3 extended spectrum cephalosporins and their combination with (3-APB)
  • Detection of OXA-48-like type D carbapenemases based on the determination of temocillin high-level resistance
  • Detection of low-level carbapenem resistance by introduction of meropenem screening concentrations
  • Analysis and interpretation after visual or automated reading according to EUCAST or CLSI standard

 

 

Please contact your local representative for availability in your country.

Not for sale in the USA. MERLIN Gesellschaft für mikrobiologische Diagnostika mbH – A Bruker Company (www.merlin-diagnostika.de)

Related products